Hi Guys,
Firstly, massive announcement today that JP Morgan Chase has just become a substantial Holder of our Company at 368,579,211 Shares! That is huge! These guys are the epitome of smart money. These Guys don't invest that kind of money based on a punt or hunch.
I certainly understand the frustration most investors are feeling at the moment. We have all been there. Nothing hurts more than watching an investment sink right before your eyes, especially when the investment had so much potential to start off.
I, like some of you, have been aboard this train for a very long time. I have watched the SP reach highs of $1.38 only to dwindle to the lows of $0.003. To say it has been a rollercoaster ride, would be an understatement. Some big mistakes were made along the way in regards to the previous trials. I am now confident they have all now been rectified.
Another sore point listed is to do with share dilution. No one in their right mind is a fan of share dilution unless, you are in our unique situation. If we required more funding down the track, then I could categorically say we are pretty much F'ed unless they consolidate the SOI. And even then, our companies credibility will be in the toilet. Thank goodness at this stage we are fully funded. If we hit the required benchmarks in the ongoing trials I believe our drug for MSA will be bought by BP very quickly. We wont have to want long to see a deal go down. Whether Alterity will be sold as a whole or just the License for MSA, I have no clue, but a deal will be done one way or another. Share consolidation in our current situation becomes totally irrelevant. Whether we consolidate or not, doesn't make one iota of difference. Personally, I hope Stamler and the BoD don't consolidate the register. Their is absolutely no advantage to Shareholders at this stage of the game.
Personally, I am committed to see this investment through. Just to short circuit a long convoluted post, I will list my reasons in point form below.
- Institutions and Sophisticated Investors recently took a $3.5 Million parcel one go. You have to ask yourself, why are these shares being picked up if ATH was a "dead duck"
- Primate study was a total success and proved both safety and an improvement for those Primates implanted with MSA
- This year is it. Our investment will either pay off big or it is dead as a dodo. It usually takes a solid 15 to 20 years for a Bio Company to get to this point in time
- At $0.004, we have nothing but blue sky ahead, it certainly doesn't need much to multiply very quickly. One piece of decent news and it will commence the travel north
- I am assuming based on the latest raise of $3.5M, we are now well funded until the Phase II double blinded placebo study at years end
- Having 3 Speakers at the prestigious ANN gathering in April this year. Why would they give us approval to have 3 speakers if we had nothing of interest to present. Also BP has a massive presence at this event
- If ATH434 is successful, Dr Stamler has mentioned that the MSA market is worth an incredible $1.1B USD. Remembering we have already been granted orphan status for this drug for the next 7 to 10 years. Nothing currently exists in the market for MSA today.
- Neurologists have already committed to prescribing our Drug if it is successful in the trials (As stated by Stamler in last presentation)
- News should start to flow through from the "Open Label Study" due this July.
They are just some of the reasons why I choose to hold and stay. Remember, this is only my opinion. You may agree or disagree, that is your prerogative. I just think this late in the game, its important to focus on the positives and the key objectives at play. The SP will do what the SP does until the results are released. If the results are the same or better than the Primate Study, then look out! If not, then I am taking my bat and ball and going home. Its that simple.
One thing is for sure, we don't have very long to wait. GLTAH...
Stockman
(20min delay)